LEXICON PHARMACEUTICALS, INC.

Lexicon Pharmaceuticals reported a net loss of $(31.8) million for Q2 2026, a significant decrease from a net income of $3.3 million in Q2 2025, primarily due to lower licensing revenue. Despite the operational loss, the company strengthened its financial position by securing a new $100 million Hercules Term Loan, with $55 million funded, and fully repaying its previous Oxford Term Loans. Additionally, Lexicon completed an equity offering and private placement in February 2026, raising approximately $96.2 million in net proceeds to support its pipeline and operations.

Lexicon Pharmaceuticals reported a net loss of $31.8 million for Q2 2026, compared to a net income of $3.3 million in Q2 2025. Total revenues significantly decreased to $0.7 million from $28.9 million year-over-year, primarily due to lower licensing revenue. The company also provided positive clinical updates, including the completion of enrollment for the Phase 3 SONATA-HCM study with top-line data expected in Q1 2027, and nearing completion of NDA resubmission activities for ZYNQUISTA® in type 1 diabetes. Additionally, Novo Nordisk's Phase 1 clinical development of LX9851 is ongoing, and the company secured a new $100 million loan facility.

Lexicon Pharmaceuticals, Inc. announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026, before market open. Management will host a conference call and live webcast at 8:30 a.m. ET on the same day to discuss the results and provide a business update. The webcast will be available on the company's investor relations website.

Lexicon Pharmaceuticals announced the completion of patient randomization for its pivotal Phase 3 SONATA-HCM clinical trial, evaluating sotagliflozin for hypertrophic cardiomyopathy. The study significantly surpassed its enrollment target of 500 patients, recruiting participants across over 130 sites in 20 countries. Topline results from the trial are expected in the first quarter of 2027, marking a key milestone for the potential treatment of symptomatic HCM.

Lexicon Pharmaceuticals announced it will present clinical data for sotagliflozin in Type 1 diabetes (T1D) and pilavapadin in diabetic peripheral neuropathic pain (DPNP) at the American Diabetes Association (ADA) 2026 Scientific Sessions. The company highlighted continued evidence of sotagliflozin's mechanistic benefits, reinforcing its potential ahead of a planned New Drug Application (NDA) resubmission for T1D, which remains on track for mid-year 2026. Presentations will include pooled analysis from inTandem trials for sotagliflozin and Phase 1 study results for pilavapadin.

Lexicon Pharmaceuticals management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:00 p.m. ET in New York City. The event will be accessible live and via replay on the company's investor relations website. Lexicon is a biopharmaceutical company focused on pioneering medicines for various conditions including neuropathic pain, hypertrophic cardiomyopathy, obesity, and metabolic disorders.

Lexicon Pharmaceuticals, Inc. announced that its management will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference. The event is scheduled for May 19, 2026, at the Nasdaq World Headquarters in New York City. A live webcast and replay of the presentation will be accessible through the company's investor relations website. Lexicon is a biopharmaceutical company focused on developing medicines for conditions such as neuropathic pain, hypertrophic cardiomyopathy, obesity, and metabolic disorders.

Lexicon Pharmaceuticals reported a significantly improved Q1 2026 with a net loss of $(1.04) million, a substantial reduction from $(25.3) million in Q1 2025. Total revenues surged to $21.1 million, primarily driven by $20 million in licensing and milestone revenue. The company strengthened its financial position by raising approximately $96.2 million through common and preferred stock issuances and secured a new $100 million Hercules Term Loan facility, using the initial $55 million tranche to repay its Oxford Term Loans. Lexicon continues to advance its pipeline, including INPEFA commercialization and clinical trials for sotagliflozin and pilavapadin.

Lexicon Pharmaceuticals reported a significantly reduced net loss of $1.0 million for Q1 2026, compared to $25.3 million in Q1 2025, driven by $20.0 million in licensing and milestone revenue. Total revenues reached $21.1 million. The company ended the quarter with a strong cash position of $199.7 million, bolstered by a $96.5 million stock sale and a new $100 million loan facility. Lexicon anticipates key clinical milestones, including SONATA-HCM enrollment completion mid-2026, ZYNQUISTA NDA resubmission mid-2026, and continued development of LX9851 by Novo Nordisk.

Lexicon Pharmaceuticals entered into a loan and security agreement with Hercules Capital, Inc. for up to $100 million, available in three tranches maturing in May 2030. The initial $55 million tranche was funded at closing and will be used to repay an existing loan facility with Oxford Finance. This new facility provides greater financial flexibility and supports upcoming regulatory and commercial milestones, with additional tranches contingent on clinical and regulatory achievements for sotagliflozin.